,i #aagth ,,congress #b;d ,session ,h4 ,r4 #gfdf ,,in ,,the ,,house ,,of ,,representatives ,may #c1 #bjbb,mr4 ,guthrie 7for himself and ,mr4 ,moulton7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend the ,federal ,food1 ,drug1 and ,cosmetic ,act to notify the public about an emerging signal concerning a medical device in order to reduce or limit the number of patients exposed to a potential risk identified based on such emerging signal1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,emerging ,signals ,modernization ,act of #bjbb4 #b4 ,public notification of an emerging signal concerning a medical device 7a7 ,technical amendments ,section #eah of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;h7 is amended-- 7#a7 by striking the section designation and heading and that follows through ,if the ,secretary determines that-- and inserting the following3 #eah4 ,notification and other remedies 7a7 ,notification 7#a7 ,in general ,if the ,secretary determines that-- 2 and 7#b7 in subsection 7a7-- 7,a7 by striking 7#a7 a device and inserting the following3 7,a7 a device 2 7,b7 by striking 7#b7 notification and inserting the following3 7,b7 notification 2 7,c7 by moving the margin of the continuation text at the end of subsection 7a7 #b ems to the right2 and 7,d7 by striking this subsection each place it appears and inserting this paragraph4 7b7 ,emerging signals ,section #eah7;a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;h7a771 as amended by subsection 7a71 is further amended by adding at the end the following3 7#b7 ,emerging signals and other notifications 7,a7 ,applicability ,this paragraph applies if the ,secretary-- 7i7 determines that a device meets the conditions described in paragraph 7#a77;,a71 and no more practicable means is available under the provisions of this ,act1 including paragraph 7#a71 to eliminate the risk described in paragraph 7#a77;,a72 or 7ii7 otherwise determines that it is necessary to notify the public about an emerging signal concerning a device in order to reduce or limit the number of patients exposed to a potential risk identified based on an emerging signal4 7,b7 ,definition of emerging signal ,in this paragraph1 the term emerging signal means new information about a marketed device-- 7i7 that supports a new causal association or a new aspect of a known association between the device and an adverse event or set of adverse events2 and 7ii7 for which the ,secretary has conducted an initial evaluation and determined that the information has the potential to impact patient management decisions or the known benefit-risk profile of the device4 7,c7 ,reliance on scientific evidence ,in considering and taking actions under this section1 the ,secretary shall-- 7i7 to the extent possible1 rely solely on valid scientific evidence2 and 7ii7 in any event1 base such actions on credible scientific evidence1 such that information that is unconfirmed1 unreliable1 or lacks sufficient strength of evidence shall not constitute an emerging signal or otherwise provide a basis for notification under this paragraph4 7,d7 ,content of public notification ,any public notification under this paragraph shall-- 7i7 include a description of the device or devices to which the notification applies2 7ii7 reflect a totality of the evidence on which the notification is based2 and 7iii7 incorporate information about the known benefits and risks of the device or devices1 including information available from the manufacturer or manufacturers4 7,e7 ,contradictory evidence ,to the extent credible scientific evidence is presented to the ,secretary that contradicts or modifies the information that serves as a potential basis for a public notification under this paragraph1 the ,secretary shall include such scientific evidence in the public notification in a manner that provides the intended audience with a complete understanding of the overall nature of information concerning the potential risk4 7,f7 ,opportunity for manufacturers to comment ,prior to issuance of a public notification under this paragraph1 the ,secretary shall-- 7i7 provide the manufacturer or manufacturers of the device or devices at issue the credible scientific evidence that is the basis for considering the public notification and the ,secretary's initial evaluation of such evidence as described in subparagraph 7,b77ii72 7ii7 to the extent the ,secretary determines that any of the credible scientific evidence described in clause 7i7 cannot be provided to manufacturers because such evidence constitutes confidential commercial information or trade secret information1 provide the manufacturer or manufacturers of the device or devices at issue with a description of the withheld evidence to the extent permissible by law and generally describe the basis for withholding such evidence2 7iii7 provide the manufacturer or manufacturers of the device or devices at issue an adequate opportunity-- 7,i7 to comment as to the nature of the potential risk and the manner and content of the potential notification under this paragraph2 7,,ii7 to share information about the potential risk2 and 7,,iii7 to offer recommendations as to the form and content of the potential notification1 including consideration of alternative forms of notification and risk mitigation2 and 7iv7 consider any input received under clause 7iii74 7,g7 ,updates ,the ,secretary shall provide periodic and timely updates to each notification under this paragraph based on new information or contrary information1 including affirmative notice in the event that the emerging signal or other source of potential risk has been determined not to apply or has otherwise been resolved or mitigated1 such that no additional actions are required4 ,for purposes of providing updates under this subparagraph1 the ,secretary shall consider information provided to the ,secretary by a manufacturer subsequent to the initial public notification4 7,h7 ,response to information provided by manufacturer ,with regard to information provided to the ,secretary by a manufacturer relating to a notification under this paragraph1 the ,secretary shall inform such manufacturer-- 7i7 how such information affects or alters the ,secretary's initial evaluation2 and 7ii7 whether the notification will be updated or rescinded as a result of such information4 7,i7 ,periodic evaluation ,at least every six months after issuance of a notification under this paragraph1 the ,secretary shall-- 7i7 evaluate current credible scientific evidence to determine if such notification should be rescinded2 and 7ii7 if the ,secretary determines such notification should be rescinded1 promptly provide notice of the rescission to the same audience and in the same manner as the original notification4 7,j7 ,revision of guidance ,not later than ,september #cj1 #bjbc1 the ,secretary shall revise the guidance of the ,food and ,drug ,administration titled ,public ,notification of ,emerging ,postmarket ,medical ,device ,signals 7,emerging ,signals71 to conform with this paragraph4 7,k7 ,report to ,congress ,not later than ,september #cj1 #bjbc1 the ,secretary shall submit to the ,committee on ,energy and ,commerce of the ,house of ,representatives and the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate a report regarding-- 7i7 how patients1 health care providers1 and the public interpret and comprehend risk-related information provided or ordered by the ,secretary relating to devices1 including reports under this section1 notifications concerning recalls1 and notifications concerning adverse events2 and 7ii7 whether the relative level of risk and appropriate mitigations for such risk are adequately understood4 7,l7 ,third party data transparency ,to the extent the ,secretary seeks to rely on data1 analysis1 or other information or findings provided by third parties that has been funded in whole or in part by1 or otherwise performed under contract with1 the ,food and ,drug ,administration1 in making a significant decision concerning one or more devices or considering issuance of an order under this section or section #ebb1 the ,secretary shall-- 7i7 obtain access to the raw datasets1 inputs1 clinical or other assumptions1 methods1 analytical code1 results1 and other components underlying or comprising the data1 analysis1 or other information or findings upon which the ,secretary seeks to rely2 and 7ii7 if such a significant decision is made1 or such an order under this section or section #ebb is under consideration1 in reliance on such data1 analysis1 or other information or findings1 provide the manufacturer or manufacturers subject to such decision or order the data1 analysis1 or other information or findings1 including the underlying raw datasets1 inputs1 clinical or other assumptions1 methods1 analytical code1 results1 and other components1 except that any such raw datasets1 inputs1 clinical or other assumptions1 methods1 analytical code1 results1 and other components that the ,secretary determines to be confidential commercial information or trade secret information may be withheld but shall be described to the manufacturer or manufacturers to the extent permissible by law4 4